Metagenomi nominates MGX-001 DC for hemophilia A; reports $274.6M cash; Q3 expenses down

Metagenomi Therapeutics, Inc.

Nominated MGX-001 as first development candidate for hemophilia A; IND-enabling activities initiated, IND filing on track for 2026.
Cash, cash equivalents and marketable securities $274.6M at Sept 30, 2024; cash runway expected into 2027.
R&D expenses $26.3M in Q3 2024 (vs $26.8M Q3 2023); G&A $7.6M (vs $7.9M).
Ionis collaboration: all four wave 1 programs in lead optimization; one to two DC nominations expected in 2025.
Novel ABE platform targets >95% of genome base pairs; SMART platform enables single-AAV delivery for neuromuscular.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.